Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01250470
Show Display Options
Rank Status Study
1 Active, not recruiting Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Recurrent Adult Brain Tumor
Interventions: Drug: Montanide ISA-51/survivin peptide vaccine;   Biological: sargramostim;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years